Live Breaking News & Updates on Pharma sector

Stay informed with the latest breaking news from Pharma sector on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Pharma sector and stay connected to the pulse of your community

Nifty: PSU banks will continue re-rating; SBI, ICICI Bank & Axis Bank poised for a breakout: Laurence Balanco

You can see from foreign flows perspective that rebound in China is detracting from some of the investment in India. I do not think it changes the longer-term trends, but we are in one of those holding patterns similar to the fourth quarter of 2023.

India , Kozhikode , Kerala , China , Laurence-balanco , Offering-college , Nifty-bank , Kotak-bank , Axis-bank , Indian-school-of-business , Leadership-excellence , Product-officer

PLI schemes attract over Rs 1.06 lakh crore investment till Dec; pharma sector gets major chunk

PLI schemes across sectors attracted significant investments by December 2023, notably in pharma and solar industries. While some sectors thrived, others like IT hardware, auto, and textiles faced tepid interest, prompting a review for scheme improvements.

Shirdi , Maharashtra , India , Glenmark-pharma , Reliance-new-energy-solar-ltd , Wockhardt-ltd , Cipla , Biocon , Shirdi-sai-electricals , Adani-infrastructure , Tata-power , Pli-schemes

market crash: Crash was expected; stay calm and invested as market will revive soon: Sandeep Raina

Sandeep Raina is not worried about the market crash. Further small cuts are possible, but it's not a bloodbath. Stay invested, the market will revive. Quality midcaps, smallcaps, and largecaps with 20% growth, good ROCE, and cash flows are worth investing. Pharma stocks like Beta Drugs, Kilpest, and Sun Pharma are interesting.

India , Kozhikode , Kerala , Lucknow , Uttar-pradesh , Sandeep-raina , Sun-pharma , Nuvama-professional-clients-group , Offering-college , Indian-school-of-business , Leadership-excellence , Executive-officer

Zydus | Sun Pharma | Lupin: Bank Nifty is way weaker than Nifty; positive on realty & pharma sectors: Meghana Malkan

Meghana Malkan believes realty and pharma sectors show potential for trade. She highlights specific stocks to watch, cautions about weak resistance for Nifty, predicts a drop in Bank Nifty, takes a break from PSU sector, and has a mixed view on the IT sector. In the case of IT, she would prefer to really adopt a wait-and-watch approach.

Lucknow , Uttar-pradesh , India , Sun-pharma , Meghana-malkan , Zydus-lifescience , Bank-nifty , Offering-college , Indian-school-of-business , Leadership-excellence , Operations-officer , Zydus-sun-pharma-lupin

Will India's pharma sector be able to come out of its China dependence?

Indian pharma industry's heavy dependence on imports for active pharmaceutical ingredients (API), key starting materials (KSM) and basic chemicals has been rather alarming, highlighting the need for a resolution.

China , India , Beijing , Chinese , Bloomberg , India-aurobindo-pharma-ltd , Product-linked-incentive , Aurobindo-pharma , Chemical-minister , Compound-annual-growth-rate , Pharma-sector

5 best mutual funds in the pharma and healthcare sector

The Indian pharmaceutical sector holds significant growth potential, yet it is crucial to acknowledge the accompanying risks and uncertainties. Before making any commitments to invest in a pharma fund, thorough research is imperative.

Mirae-asset-healthcare-fund , Diagnosticsp-hd-fund , Pharma-healthcare-fund , Healthcare-opportunities-fund , Tata-india-pharma-heathcare-fund , Pharma-healthcare , Pharma-and-healthcare-funds , Sectoral-fund , Thematic-funds , Pharmaceutical-sector , Nifty-pharma-index

Top 5 pharma and healthcare mutual funds

Exploring the growth potential of the Indian pharmaceutical sector requires careful consideration of risks and uncertainties, demanding thorough research before investing in a pharma fund.

Pharma-and-healthcare-funds , Sectoral-fund , Thematic-funds , Pharmaceutical-sector , Nifty-pharma-index , Pharma-sector , Healthcare-sector , Mutual-funds , Best-mutual-funds , Top-mutual-funds ,

consumer stocks to buy: Play for the bigger themes and bet on India, says Samir Arora

Samir Arora of Helios Capital discusses valuation, investment strategies, and risk management in the Indian market. He emphasizes the missed opportunity in the pharma sector and the underperformance of the consumer sector. He said willing to buy consumer stocks at 40-50 PE if the companies are growing 25-30% per annum for the next few years at least. That is the only thing we will buy in consumer even if the valuations are high. That is why we have Zomato and Varun Beverages .

Russia , Lucknow , Uttar-pradesh , India , Ukraine , China , Taiwan , Samir-arora , Indian-school-of-business , Offering-college , Helios-capital , Leadership-excellence

PSU banks: Not very keen on pharma now; all the fun and action are in PSU banks: Andrew Holland

Andrew Holland, CEO of Avendus Capital Alternate Strategies, believes that PSU banks are performing well while private banks face challenges. He also comments on the rotational market, pharma and IT sectors, OMCs, metal stocks, and the global market dynamics. He also says, he likes metal stocks a lot, That is an area which will see continued rise over the course of the next month.

Lucknow , Uttar-pradesh , India , China , Kozhikode , Kerala , United-kingdom , Andrew-holland , Nasdaq , Indian-school-of-business , Offering-college , Avendus-capital-public-markets-alternate-strategies